Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment.
de Nie I, de Blok CJM, van der Sluis TM, Barbé E, Pigot GLS, Wiepjes CM, Nota NM, van Mello NM, Valkenburg NE, Huirne J, Gooren LJG, van Moorselaar RJA, Dreijerink KMA, den Heijer M. de Nie I, et al. Among authors: van der sluis tm, van mello nm, van moorselaar rja. J Clin Endocrinol Metab. 2020 Sep 1;105(9):e3293-9. doi: 10.1210/clinem/dgaa412. J Clin Endocrinol Metab. 2020. PMID: 32594155 Free PMC article.
Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM, Meuleman EJ, van Moorselaar RJ, Bui HN, Blankenstein MA, Heijboer AC, Vis AN. van der Sluis TM, et al. Among authors: van moorselaar rj. BJU Int. 2012 Jan;109(2):183-8. doi: 10.1111/j.1464-410X.2011.10652.x. Epub 2011 Oct 12. BJU Int. 2012. PMID: 21992404 Review.
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR. van den Eertwegh AJ, et al. Among authors: van der sluis tm, van moorselaar rj, van den berg hp. Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10. Lancet Oncol. 2012. PMID: 22326922
Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
van der Sluis TM, Bui HN, Meuleman EJ, Heijboer AC, Hartman JF, van Adrichem N, Boevé E, de Ronde W, van Moorselaar RJ, Vis AN. van der Sluis TM, et al. Among authors: van moorselaar rj, van adrichem n. J Urol. 2012 May;187(5):1601-6. doi: 10.1016/j.juro.2011.12.063. Epub 2012 Mar 14. J Urol. 2012. PMID: 22425112
21 results